23:36 , Jul 15, 2019 |  BC Extra  |  Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that inhibits a target unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma...
22:58 , Jul 10, 2019 |  BC Extra  |  Company News

Management tracks: Maze, Tiaki, NED, Annexon and more

Maze Therapeutics (Redwood City, Calif.) said Richard Scheller joined its board. Scheller, who in January became chairman of R&D at BridgeBio Pharma Inc. (NASDAQ:BBIO), was CSO and head of therapeutics at personal genetics company 23andMe...
21:36 , May 16, 2019 |  BC Extra  |  Clinical News

May 16 ASCO Quick Takes: Aduro ends MM trial; plus Puma, PharmaMar, Genocea, J&J

Abstracts were released late Wednesday ahead of the American Society of Clinical Oncology meeting starting May 31 in Chicago. See below for BioCentury's second round of Quick Takes on selected abstracts (see "May 15 ASCO...
22:34 , Apr 22, 2019 |  BC Extra  |  Company News

Management tracks: MeiraGTx, Retrophin, Aduro

MeiraGTx Holdings plc (NASDAQ:MGTX) said Katherine Breedis stepped down as CFO on April 16, a little over six months after she joined the gene therapy company. MeiraGTx said COO Richard Giroux will take on the...
00:27 , Mar 8, 2019 |  BC Innovations  |  Targets & Mechanisms

Flipping the switch in immuno-oncology

Tumor myeloid cells are emerging as prime candidates for filling a hole in the immuno-oncology tool box, offering targets that can simultaneously release the brakes and rev up the gas in the immune system. As...
19:48 , Feb 1, 2019 |  BC Week In Review  |  Company News

Aduro reducing headcount by 37%, focusing on STING

Aduro Biotech Inc. (NASDAQ:ADRO) said it will reduce headcount by 37% to focus on discovery and development of compounds against STING, via its deals with Novartis AG (NYSE:NVS; SIX:NOVN) and Eli Lilly and Co. (NYSE:LLY),...
13:52 , Jan 29, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Mouse studies suggest polymer vesicles loaded with the STING agonist cGAMP could help treat melanoma. The vesicles consist of cGAMP encapsulated in a polyethylene glycol (PEG)-based polymer membrane based on pH-sensitive, cationic diethylamino-based...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Lilly licenses Aduro's STING inhibitors

Eli Lilly and Co. (NYSE:LLY) received an exclusive license from Aduro Biotech Inc. (NASDAQ:ADRO) for its cGAS-STING inhibitor platform to develop immunotherapies for autoimmune and inflammatory diseases. Aduro will receive $12 million up front and...
00:04 , Dec 21, 2018 |  BC Extra  |  Preclinical News

STING inhibitors could treat NASH

A paper in this week's edition of The Journal of Clinical Investigation expands the list of indications that could be treated by targeting the STING pathway, suggesting that inhibiting the cytosolic DNA sensor could help...